therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-8156РостГМУ10.21886/2712-8156-2020-1-2-102-108therapeutic-29Research ArticleОБЗОРЫREVIEWSВлияние статинов на течение новой коронавирусной инфекции: миф или реальность?The impact of statins on the course of a new coronavirus infection: myth or reality?https://orcid.org/0000-0002-9659-7010ТарловскаяЕ. И.TarlovskyE. I.

Тарловская Екатерина Иосифовна — доктор медицинских наук, профессор, заведующий кафедрой терапии и кардиологии

Нижний Новгород

Еkaterina I. Tarlovsky — Dr. Sci. (Med.), Professor, head of the Department of therapy and cardiology

Nizhny Novgorod

etarlovskaya@mail.ruФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииРоссияVolga Research Medical UniversityRussian Federation20200608202012102108Copyright © Тарловская Е.И., 20202020Тарловская Е.И.Tarlovsky E.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/29

В обзоре представлены данные, касающиеся нелипидных эффектов статинов, которые могут быть полезны при лечении пациентов с новой коронавирусной инфекцией. Обсуждаются такие эффекты статинов, как противоспалительный, иммуномодулирующий, антитромботический, а также восстановление дисфункции эндотелия и нормализация фибринолиза. Обсуждается влияние статинов на проникновение SARS-CoV2 в клетку и репликацию вируса. Приведены последние данные наблюдательных клинических исследований по влиянию статинов на тяжесть течения новой коронавирусной инфекции.

The review presents data regarding the non-lipid effects of statins that may be useful in the treatment of patients with new coronavirus infection. The effects of statins such as antiflammatory, immunomodulatory, antithrombotic, as well as the restoration of endothelial dysfunction and the normalization of fibrinolysis are discussed. The effect of statins on SARS-CoV2 entry into the cell and viral replication is discussed. Recent data from observational clinical studies on the effect of statins on the severity of the course of a new coronavirus infection are presented.

обзорстатиныCOVID-19overviewstatinsCOVID-19ReferencesDocherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 2020.04.23.20076042. https://doi.org/10.1101/2020.04.23.20076042Annemarie B Docherty, Ewen M Harrison, Christopher A Green et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv doi: https://doi.org/10.1101/2020.04.23.20076042Li B, Yang J, Zhao F, Zhi L, Wang X et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531–538. https://doi.org/10.1007/s00392-020-01626-9Li B1, Yang J2,3, Zhao F4, Zhi L5, Wang X2 et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 Mar 11. doi: 10.1007/s00392-020-01626-9. [Epub ahead of print]Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;Feb 24. https://doi.org/10.1001/jama.2020.2648.Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020. Doi: 10.1001 / jama.2020.2648Clemente GS, Rickmeier J, Antunes IF, Zarganes-Tzitzikas T, Dömling A, Ritter T, et al. [18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statinrelated mechanisms of action. EJNMMI Res. 2020;10(1):34. https://doi.org/10.1186/s13550-020-00622-4.Gonçalo S. Clemente,1 Jens Rickmeier,2 Inês F. Antunes, [18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action EJNMMI Res. 2020; 10: 34. Published online 2020 Apr 15. doi: 10.1186/s13550-020-00622-4Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation. 2002;105(16):2000-4. https://doi.org/10.1161/01.cir.0000012528.89469.8e.Ambrose JA1, Martinez EE A new paradigm for plaque stabilization. Circulation. 2002 Apr 23;105(16):2000-4. . DOI: 10.1161/01.cir.0000012528.89469.8eAikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103(2):276-83. https://doi.org/10.1161/01.cir.103.2.276.Aikawa M1, Rabkin E, Sugiyama S et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001 Jan 16;103(2):276-83.Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5.7. Zsuzsanna Varga, Andreas J Flammer, Peter Steiger et al. Endothelial cell infection and endotheliitis in COVID-19 Published:April 20, 2020 DOI:https://doi.org/10.1016/S0140-6736(20)30937-5Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559-1561. https://doi.org/10.1111/jth.14849.Connors JM1, Levy JH2. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14849. [Epub ahead of print]Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020; Mar 27. https://doi.org/10.1001/jamacardio.2020.1286. Epub ahead of print.Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1286Hu T, Chen B, Zhou S, Mao J. Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. Int J Clin Exp Pathol. 2018;11(8):3925-3933. PMID: 31949780.Hu T1, Chen B2, Zhou S2, Mao J2. Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. Int J Clin Exp Pathol. 2018 Aug 1;11(8):3925-3933. eCollection 2018.Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T, et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. J Clin Med. 2019;8(12):2051. https://doi.org/10.3390/jcm8122051.Gorabi AM1, Kiaie N1, Hajighasemi S2, Banach M3, Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. J Clin Med. 2019 Nov 22;8(12). pii: E2051. doi: 10.3390/jcm8122051.Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and metaanalysis. Lancet Haematol. 2017;4(2):e83-e93. https://doi.org/10.1016/S2352-3026(16)30184-3.Kunutsor SK1, Seidu S2, Khunti K2 Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis.. Lancet Haematol. 2017 Feb;4(2):e83-e93. doi: 10.1016/S2352-3026(16)30184-3. Epub 2017 Jan 13.Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J. 2017;38(20):1608-1612. https://doi.org/10.1093/eurheartj/ehx107Kunutsor SK1, Seidu S2,3, Khunti K2,3 Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.. Eur Heart J. 2017 May 21;38(20):1608-1612. doi: 10.1093/eurheartj/ehx107.Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-8. https://doi.org/10.1056/NEJMoa042378.Ridker PM1, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators N Engl J Med. 2005 Jan 6;352(1):20-8.de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307-16. https://doi.org/10.1001/jama.292.11.1307.de Lemos JA1, Blazing MA, Wiviott SD, Lewis EF, Fox KA et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 Sep 15;292(11):1307-16. Epub 2004 Aug 30.Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64-70. https://doi.org/10.1001/jama.286.1.64.Albert MA1, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001 Jul 4;286(1):64-70.Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-65. https://doi.org/10.1056/NEJM200106283442601.Ridker PM1, Rifai N, Clearfield M, Downs JR, Weis SE, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001 Jun 28;344(26):1959-65.Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of lowdensity lipoprotein cholesterol reduction. Circulation. 2002;106(12):1447-52. https://doi.org/10.1161/01.cir.0000029743.68247.31.Plenge JK1, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction Circulation. 2002 Sep 17;106(12):1447-52..Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 2006;54(2):579-86. https://doi.org/10.1002/art.21564Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 2006;54:579-586Geng J, Xu H, Yu X, Xu G, Cao H, Lin G, et al. Rosuvastatin protects against oxidized low density lipoprotein induced endothelial cell injury of atherosclerosis in vitro. Mol Med Rep. 2019;19(1):432-440. https://doi.org/10.3892/mmr.2018.9666.Geng J., Xu H., Yu X., Xu G., Cao H., Lin G., Sui D. Rosuvastatin protects against oxidized lowdensity lipoproteininduced endothelial cell injury of atherosclerosis in vitro. Mol. Med. Rep. 2019;19:432–440. doi: 10.3892/mmr.2018.9666.Yinjuan T, Jianjun W, Yinglu G, Weijun C, Weijun T, Mingying L. [Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats]. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(11):1265-1272. https://doi.org/10.12122/j.issn.1673-4254.2019.11.01. (in Chineese)Yinjuan T, Jianjun W, Yinglu G, Weijun C, Weijun T, Mingying L. Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(11):1265-1272. doi:10.12122/j.issn.1673-4254.2019.11.Hostenbach S, D'Haeseleer M, Kooijman R, De Keyser J. Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis. Front Pharmacol. 2020;10:1491. https://doi.org/10.3389/fphar.2019.01491Hostenbach S1, D'Haeseleer M1,2,3, Kooijman R2, De Keyser J1,2,4 Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis. Front Pharmacol. 2020 Jan 8;10:1491. doi: 10.3389/fphar.2019.01491. eCollection 2019.Aslam M, Troidl C, Tanislav C, Rohrbach S, Gündüz D, Hamm CW. Inhibition of Protein Prenylation of GTPases Alters Endothelial Barrier Function. Int J Mol Sci. 2019;21(1):2. https://doi.org/10.3390/ijms21010002.Aslam M1,2,3, Troidl C1,2,3, Tanislav C4, Rohrbach S5, Gündüz D1,6, Hamm CW1,3 Inhibition of Protein Prenylation of GTPases Alters Endothelial Barrier Function. Int J Mol Sci. 2019 Dec 18;21(1). pii: E2. doi: 10.3390/ijms21010002.John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149(3):473. https://doi.org/10.1016/j.ahj.2004.06.027John S1, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005 Mar;149(3):473.Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103(18):2248-53. https://doi.org/10.1161/01.cir.103.18.2248.Geng J., Xu H., Yu X., Xu G., Cao H., Lin G., Sui D. Rosuvastatin protects against oxidized lowdensity lipoproteininduced endothelial cell injury of atherosclerosis in vitro. Mol. Med. Rep. 2019;19:432–440. doi: 10.3892/mmr.2018.9666.Chang SN, Wu CK, Lai LP, Chiang FT, Hwang JJ, Tsai CT. The effect and molecular mechanism of statins on the expression of human anti-coagulation genes. Cell Mol Life Sci. 2019;76(19):3891-3898. https://doi.org/10.1007/s00018-019-03100-w.Undas A1, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001 May 8;103(18):2248-53.Violi F, Carnevale R, Pastori D, Pignatelli P. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc Med. 2014;24(4):142-8. https://doi.org/10.1016/j.tcm.2013.09.006.Chang SN1,2,3, Wu CK2, Lai LP2, Chiang FT2,4, Hwang JJ1,2, Tsai CT5,6,7Cell Mol Life Sci. The effect and molecular mechanism of statins on the expression of human anti-coagulation genes. 2019 Oct;76(19):3891-3898. doi: 10.1007/s00018-019-03100-w. Epub 2019 May 3.Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/ Rho-kinase and Akt pathways. Circulation. 2002;105(15):1756- 9. https://doi.org/10.1161/01.cir.0000015465.73933.3b.Violi F1, Carnevale R2, Pastori D2, Pignatelli P2. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc Med. 2014 May;24(4):142-8. doi: 10.1016/j.tcm.2013.09.006. Epub 2013 Oct 2.Schol-Gelok S, van der Hulle T, Biedermann JS, van Gelder T, Klok FA, van der Pol LM, et al. Clinical effects of antiplatelet drugs and statins on D-dimer levels. Eur J Clin Invest. 2018;48(7):e12944. https://doi.org/10.1111/eci.12944.Eto M1, Kozai T, Cosentino F, Joch H, Lüscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways Circulation. 2002 Apr 16;105(15):1756-9.. DOI: 10.1161/01.cir.0000015465.73933.3bOesterle A, Liao JK. The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Curr Vasc Pharmacol. 2019;17(3):222-232. https://doi.org/10.2174/1570161116666180817155058.Undas A1, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001 May 8;103(18):2248-53.Laufs U, Gertz K, Huang P, Nickenig G, Böhm M, Dirnagl U, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31(10):2442-9. https://doi.org/10.1161/01.str.31.10.2442.Schol-Gelok S1, van der Hulle T2, Biedermann JS3, van Gelder T1, Klok FA et al. Clinical effects of antiplatelet drugs and statins on D-dimer levels. Eur J Clin Invest. 2018 Jul;48(7):e12944. doi: 10.1111/eci.12944. Epub 2018 May 13.Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(1):58-63. https://doi.org/10.1161/01.atv.0000043456.48735.20.Oesterle A1, Liao JK1 The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Curr Vasc Pharmacol. 2019;17(3):222-232. doi: 10.2174/1570161116666180817155058.Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol. 2010;159(6):1294-303. https://doi.org/10.1111/j.1476-5381.2009.00612.x.Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31(10):2442–2449Kagami S, Owada T, Kanari H, Saito Y, Suto A, Ikeda K, et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol. 2009;21(6):679-89. https://doi.org/10.1093/intimm/dxp037.Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(1):58–63.Gilbert R, Al-Janabi A, Tomkins-Netzer O, Lightman S. Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis. Porto Biomed J. 2017;2(2):33-39. https://doi.org/10.1016/j.pbj.2017.01.006.Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol. 2010;159(6):1294–1303.Jameel A, Ooi KG, Jeffs NR, Galatowicz G, Lightman SL, Calder VL. Statin Modulation of Human T-Cell Proliferation, IL-1β and IL-17 Production, and IFN-γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents. Int J Inflam. 2013;2013:434586. https://doi.org/10.1155/2013/434586.Kagami S, Owada T, Kanari H, et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol. 2009;21(6):679–689.Krysiak R, Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol. 2011;57(4):505-12. https://doi.org/10.1097/FJC.0b013e318211703b.Gilbert R1,2, Al-Janabi A1,2, Tomkins-Netzer O1,2, Lightman S1,2. Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis. Porto Biomed J. 2017 Mar-Apr;2(2):33-39. doi: 10.1016/j.pbj.2017.01.006. Epub 2017 Mar 1.Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7(6):687-92. https://doi.org/10.1038/89058.Jameel A1, Ooi KG, Jeffs NR, Galatowicz G, Lightman SL, Calder VL. Statin Modulation of Human T-Cell Proliferation, IL-1β and IL-17 Production, and IFN-γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents. Int J Inflam. 2013;2013:434586. doi: 10.1155/2013/434586. Epub 2013 Sep 18.Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio. 2015;6(4):e01120. https://doi.org/10.1128/mBio.01120-15.Krysiak R1, Okopien B The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia.. J Cardiovasc Pharmacol. 2011 Apr;57(4):505-12. doi: 10.1097/FJC.0b013e318211703b.Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT, et al. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. mBio. 2015;6(3):e00638-15. https://doi.org/10.1128/mBio.00638-15.Weitz-Schmidt G1, Welzenbach K, Brinkmann V, Kamata T, Kallen J et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site., Nat Med. 2001 Jun;7(6):687-92. DOI: 10,1038 / 89058Yuan X, Deng Y, Guo X, Shang J, Zhu D, Liu H. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway. Biochem Biophys Res Commun. 2014;446(1):292-7. https://doi.org/10.1016/j.bbrc.2014.02.091.Yuan S1. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio. 2015 Aug 11;6(4):e01120. doi: 10.1128/mBio.01120-15.Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99:417–35. https://doi.org/10.1016/j.antiviral.2013.06.018Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT, Baric RS. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. 2015. mBio 6(3):e00638-15. doi:10.1128/mBio.00638-15.Fedson DS. Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother. 2018;14(3):790-795. https://doi.org/10.1080/21645515.2017.1378292.Yuan X, Deng Y, Guo X, Shang J, Zhu D, Liu H. 2014. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway. Biochem Biophys Res Commun 446:292–297. doi:10.1016/j.bbrc.2014.02.091.Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int. 2014;2014:872370. https://doi.org/10.1155/2014/872370.Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. (2013) 99:417–35. 10.1016/j.antiviral.2013.06.018Kumaki Y, Morrey JD, Barnard DL. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol. 2012;7(8):801-818. https://doi.org/10.2217/fvl.12.71Fedson DS. Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother. (2018) 14:790–5. 10.1080/21645515.2017.1378292Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Version 2. Proc Natl Acad Sci U S A. 2007;104(30):12479- 81. https://doi.org/10.1073/pnas.0705289104.Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int. (2014) 2014:872370. 10.1155/2014/872370Belser JA, Szretter KJ, Katz JM, Tumpey TM. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology. 2013;439(1):42-6. https://doi.org/10.1016/j.virol.2013.01.017.Kumaki Y, Morrey JD, Barnard DL. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol. (2012) 7:801–18. 10.2217/fvl.12.71Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, et al. The effect of rosuvastatin in a murine model of influenza A infection. PLoS One. 2012;7(4):e35788. https://doi.org/10.1371/journal.pone.0035788.Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci USA. (2007) 104:12479–81. 10.1073/pnas.0705289104Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006-12. https://doi.org/10.1378/chest.06-1997.Belser JA, Szretter KJ, Katz JM, Tumpey TM. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology. (2013) 439:42–6. 10.1016/j.virol.2013.01.017Atamna A, Babitch T, Bracha M, Sorek N, Haim BZ, Elis A, et al. Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza. Eur J Clin Microbiol Infect Dis. 2019;38(12):2341-2348. https://doi.org/10.1007/s10096-019-03684-y.Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, et al. . The effect of rosuvastatin in a murine model of influenza A infection. PLoS ONE. (2012) 7:e35788. 10.1371/journal.pone.0035788Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratoryconfirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205(1):13-9. https://doi.org/10.1093/infdis/jir695.Frost FJ1, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007 Apr;131(4):1006-12. DOI: 10.1378/chest.06-1997Pawelka E, Karolyi M, Daller S, Kaczmarek C, Laferl H, Niculescu I, et al. Influenza virus infection: an approach to identify predictors for in-hospital and 90-day mortality from patients in Vienna during the season 2017/18. Infection. 2020;48(1):51-56. https://doi.org/10.1007/s15010-019-01335-0.Atamna A1,2, Babitch T3,4, Bracha M3, Sorek N5, Haim BZ5 et al. Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza. Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2341-2348. doi: 10.1007/s10096-019-03684-y. Epub 2019 Aug 28.Fedson DS. A practical treatment for patients with Ebola virus disease. J Infect Dis. 2015;211(4):661-2. https://doi.org/10.1093/infdis/jiu474.Vandermeer ML1, Thomas AR, Kamimoto L, Reingold A, Gershman K Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis. 2012 Jan 1;205(1):13-9. doi: 10.1093/infdis/jir695. Epub 2011 Dec 13.Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, et al. Simvastatin decreases lipopolysaccharideinduced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009;179(12):1107-14. https://doi.org/10.1164/rccm.200810-1584OC.Pawelka E1, Karolyi M2, Daller S3, Kaczmarek C3, Laferl H Influenza virus infection: an approach to identify predictors for in-hospital and 90-day mortality from patients in Vienna during the season 2017/18. Infection. 2020 Feb;48(1):51-56. doi: 10.1007/s15010-019-01335-0. Epub 2019 Jun 15.Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock. 2009;31(5):500-6. https://doi.org/10.1097/SHK.0b013e318189017a.Fedson DS. 2015. A practical treatment for patients with Ebola virus disease. J Infect Dis 21:661–662. doi:10.1093/infdis/jiu474.Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, et al. Angiotensinconverting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep. 2015;5:8209. https://doi.org/10.1038/srep08209.Shyamsundar M, McKeown STW, O'Kane CM, Craig TR, Brown V et al. Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179:1107–1114. doi:10.1164/rccm.200810-1584OC.Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4(21):421. https://doi.org/10.21037/atm.2016.11.03.Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, Qi J, Xiao Z. 2009. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 3:500–506. doi:10.1097/SHK.0b013e318189017a.Fedson DS, Jacobson JR, Rordam OM, Opal SM. Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers. mBio. 2015;6(3):e00716. https://doi.org/10.1128/mBio.00716-15.Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, Zhou M, Jiang W. 2015. Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep 5:8209. doi:10.1038/srep08209.Fedson DS, Rordam OM. Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 2015;36:80–84. https://doi.org/10.1016/j.ijid.2015.04.019Fedson DS. 2016. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med 4:421. doi:10.21037/atm.2016.11.03.Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a LongLived Enemy. Front Immunol. 2019;10:531. https://doi.org/10.3389/fimmu.2019.00531.Fedson DS, Jacobson JR, Rordam OM, Opal SM. 2015. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. mBio 6:e00716-15. doi:10.1128/mBio.00716-15.Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490-496. https://doi.org/10.5114/aoms.2020.94655.Fedson DS, Rordam OM. 2015. Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 36:80–84. doi:10.1016/j.ijid.2015.04.019De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J Am Med Dir Assoc. 2020;21(7):909–914. e2. https://doi.org/10.1016/j.jamda.2020.06.018.Pizzorno A1, Padey B1, Terrier O1, Rosa-Calatrava M1. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. Front Immunol. 2019 Mar 19;10:531. doi: 10.3389/fimmu.2019.00531. eCollection 2019.Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. InHospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020:S1550-4131(20)30316-8. https://doi.org/10.1016/j.cmet.2020.06.015.Mehra M, Desai S. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2007621Rodrigues-Diez RR, Tejera-Muñoz A, Marquez-Exposito L, Rayego-Mateos S, Santos Sanchez L, Marchant V, et al. Statins: Could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020:10.1111/bph.15166. https://doi.org/10.1111/bph.15166. Epub ahead of print.Anton De Spiegeleer, Antoon Bronselaer, James T Teo, Geert Byttebier et al. The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents doi: https://doi.org/10.1101/2020.05.11.20096347Scicali R, Di Pino A, Piro S, Rabuazzo AM, Purrello F. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects? Nutr Metab Cardiovasc Dis. 2020;30(7):1068-1069. https://doi.org/10.1016/j.numecd.2020.05.003.Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 [published online ahead of print, 2020 Jun 24]. Cell Metab. 2020;S1550-4131(20)30316-8. doi:10.1016/j.cmet.2020.06.015Neufeldt CJ, Cortese M, Acosta EG, Bartenschlager R. Rewiring cellular networks by members of the Flaviviridae family. Nat Rev Microbiol. 2018;16(3):125-142. https://doi.org/10.1038/nrmicro.2017.170.Rodrigues-Diez RR, Tejera-Muñoz A, Marquez-Exposito L, et al. Statins: Could an old friend help the fight against COVID-19? [published online ahead of print, 2020 Jun 19]. Br J Pharmacol. 2020;10.1111/bph.15166. doi:10.1111/bph.15166Glende J, Schwegmann-Wessels C, Al-Falah M, Pfefferle S, Qu X, Deng H, et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensinconverting enzyme 2. Virology. 2008;381(2):215-21. https://doi.org/10.1016/j.virol.2008.08.026.Scicali R, Di Pino A, Piro S, Rabuazzo AM, Purrello F. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?. Nutr Metab Cardiovasc Dis. 2020;30(7):1068-1069. doi:10.1016/j.numecd.2020.05.003Soto-Acosta R, Mosso C, Cervantes-Salazar M, Puerta-Guardo H, Medina F, Favari L, et al. The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. Virology. 2013;442(2):132-47. https://doi.org/10.1016/j.virol.2013.04.003.Neufeldt C.J., Cortese M., Acosta E.G., Bartenschlager R. Rewiring cellular networks by members of the Flaviviridae family. Nat Rev Microbiol. 2018;16:125–142. doi: 10.1038/nrmicro.2017.170.Шляхто Е.В., Конради А.О., Арутюнов Г.П., Арутюнов А.Г., Баутин А.Е., Бойцов С.А., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. https://doi.org/10.15829/1560-4071-2020-3-3801Glende J., Schwegmann-Wessels C., Al-Falah M., Pfefferle S., Qu X., Deng H. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology. 2008;381:215–221. doi: 10.1016/j.virol.2008.08.026.Шляхто Е.В., Арутюнов Г.П., Беленков Ю.Н., Тарловская Е.И., Конради А.О., Панченко Е.П., и др. Применение статинов, антикоагулянтов, антиагрегантов и антиаритмических препаратов у пациентов с COVID-19. Кардиология. 2020;60(6):4–14. https://doi.org/10.18087/cardio.2020.6.n1180Soto-Acosta R., Mosso C., Cervantes-Salazar M., Puerta-Guardo H., Medina F., Favari L. The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. Virology. 2013;442:132–147. doi: 10.1016/j.virol.2013.04.003.Арутюнов Г.П., Козиолова Н.А., Болдина М.В., Батюшин М.М., Аметов А.С., Арутюнов А.Г., и др. Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2. Терапевтический архив. 2020;92(9). https://doi.org/10.26442/00403660.2020.09.000703Шляхто Е.В., Конради А.О., Арутюнов Г.П. и соавт. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. doi:10.15829/1560-4071-2020-3-3801Шляхто Е.В., Арутюнов Г.П., Беленков Ю.Н. и соавт. Применение статинов, антикоагулянтов, антиагрегантов и антиаритмических препаратов у пациентов с COVID-19. Кардиология. 2020;60(6):4–14. https://doi.org/10.18087/cardio.2020.6.n1180Шляхто Е.В., Арутюнов Г.П., Беленков Ю.Н. и соавт. Применение статинов, антикоагулянтов, антиагрегантов и антиаритмических препаратов у пациентов с COVID-19. Кардиология. 2020;60(6):4–14. https://doi.org/10.18087/cardio.2020.6.n1180Арутюнов Г.П., Тарловская Е.И., Козиолова Н.А. и соавт. Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2. «Терапевтический архив». 2020; 92 (9). DOI: 10.26442/00403660.2020.09.000703Арутюнов Г.П., Тарловская Е.И., Козиолова Н.А. и соавт. Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2. «Терапевтический архив». 2020; 92 (9). DOI: 10.26442/00403660.2020.09.000703ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 10 June 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-GuidanceESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 10 June 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-GuidanceMassachusetts General Hospital. Version 2.0 4/10/2020 https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/rationale-for-consideration-of-statins-for-COVID-19-patient.pdfMassachusetts General Hospital. Version 2.0 4/10/2020 https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/rationale-for-consideration-of-statins-for-COVID-19-patient.pdf

The authors declare that there are no conflicts of interest present.